Original Paper

Urine Proteomics Revealed a Significant Correlation Between Urine-Fibronectin Abundance and Estimated-GFR Decline in Patients with Bardet-Biedl Syndrome

Marianna Caterino^{a,b} Miriam Zacchia^d Michele Costanzo^{a,b,c} Giuliana Bruno^e
Davide Arcaniolo^f Francesco Trepiccione^d Rosa Anna Siciliano^g
Maria Fiorella Mazzeo^g Margherita Ruoppolo^{a,b,c} Giovambattista Capasso^d

^aDipartimento di Medicina Molecolare e Biotecnologie Mediche, Università degli Studi di Napoli, "Federico II", Naples, ^bCEINGE Biotecnologie Avanzate, Naples, ^cAssociazione culturale DiSciMuS, Casoria, Naples, ^dDivision of Nephrology, Department of Cardio-thoracic and Respiratory Sciences, University of Campania "Luigi Vanvitelli", Naples, ^eIRGS Biogem, Via Camporeale, Ariano Irpino, Avellino, ^fUrology Unit, University of Campania "Luigi Vanvitelli", Naples, ^gIstituto di Scienze dell' Alimentazione, CNR Avellino, Italy

Key Words

Bardet-Biedl Syndrome • Kidney dysfunction • Urine proteome • Fibronectin • GFR decline

Abstract

Background:/Aims: Renal disease is a common cause of morbidity in patients with Bardet-Biedl syndrome (BBS), however the severity of kidney dysfunction is highly variable. To date, there is little information on the pathogenesis, the risk and predictor factors for poor renal outcome in this setting. The present study aims to analyze the spectrum of urinary proteins in BBS patients, in order to potentially identify 1) disease-specific proteomic profiles that may differentiate the patients from normal subjects; 2) urinary markers of renal dysfunction. **Methods:** Fourteen individuals (7 males and 7 females) with a clinical diagnosis of BBS have been selected in this study. A pool of 10 aged-matched males and 10 aged-matched females have been used as controls for proteomic analysis. The glomerular filtration rate (eGFR) has been estimated using the CKD-EPI formula. Variability of eGFR has been retrospectively assessed calculating average annual eGFR decline (Δ eGFR) in a mean follow-up period of 4 years (3-7). **Results:** 42 proteins were significantly over- or under-represented in BBS patients compared with controls; the majority of these proteins are involved in fibrosis, cell adhesion and extracellular matrix organization. Statistic studies revealed a significant correlation between urine fibronectin (u-FN) ($r^2=0.28$; $p<0.05$), CD44 antigen ($r^2=0.35$; $p<0.03$) and lysosomal alfa glucosidase ($r^2=0.27$;

M. Caterino and M. Zacchia contributed equally to this paper.

Miriam Zacchia

Division of Nephrology, Department of Cardio-Thoracic and Respiratory Sciences, University of Campania "Luigi Vanvitelli", via Pansini n. 5, Policlinico Nuovo, 80131, Naples (Italy)
Tel. +0039-0815666650 E-Mail miriamzacchia@virgilio.it

$p < 0.05$) abundance with the eGFR. In addition, u-FN ($r^2 = 0.2389$; $p < 0.05$) was significantly correlated with Δ eGFR. **Conclusion:** The present study demonstrates that urine proteome of BBS patients differs from that of normal subjects; in addition, kidney dysfunction correlated with urine abundance of known markers of renal fibrosis.

© 2018 The Author(s)
Published by S. Karger AG, Basel

Introduction

Kidney dysfunction is a well-known clinical feature of BBS patients; however, its pathogenesis is still largely unknown. The syndrome has a genetic origin, and to date 21 genes have been associated with human BBS but it is presumable that other unknown genes are yet to be discovered [1]. Even though many efforts have been devoted to address genotype-phenotype correlation, there is still little information on this issue [2-4].

Renal abnormalities in BBS patients are both structural and functional. The majority of BBS patients show structural defects of the kidney and the urinary tract [5]; kidney dysfunction ranges from renal hyposthenuria to the end stage renal disease (ESRD) [6-9]. Whether the defective ability to concentrate the urine is an early marker of kidney dysfunction is currently unknown [10-13]. The molecular basis of kidney dysfunction is poorly understood. The BBS genes encode proteins that are mainly localized to the centrosome and regulate the function of the primary cilium (PC) [14]. Several studies have linked the disruption of cilia homeostasis with defects in renal development and cysts formation, thus BBS is considered the result of ciliary dysfunction and is included in the group of diseases named *ciliopathies*. Mouse models of BBS have shown that *BBS2*, *BBS4* and *BBS10* depletion lead to systemic-related renal disease [15, 16]. In addition, *in vitro* studies have shown that *BBS10* is implicated in the mechanisms mediating water re-absorption along the collecting duct (CD) [17, 18]. The role of BBS genes in human kidney disease is largely unknown. In the recent years, urinary proteomic investigation has been applied to clinical medicine, allowing identification of up- or down-regulated proteins, that may help to clarify the pathophysiology of kidney dysfunction and to discover disease biomarkers [19]. The present study is the first investigation on urine proteome in BBS patients. Our results demonstrate that these patients have a unique urine protein profile. In addition, the correlation between altered proteins and kidney dysfunction may shed light in understanding the patho-physiology of renal disease and may help to predict renal outcome.

Materials and Methods

Participants

This study was performed in adherence to the Declaration of Helsinki and was approved by Institution Review Board. All patients or their legal representatives gave their written informed consent. A group of 14 adult individuals with a clinical diagnosis of BBS according to Beales criteria [5] were enrolled in the study. Retinal degeneration was assessed by ophthalmological testings. Obesity was defined as body mass index over 30 kg/m². Learning disabilities included defects in writing, reading, speaking, besides deficits of memory and coordination. The patients underwent biochemical analyses to address renal function; in addition, kidney ultrasound was performed. The GFR was estimated with CKD-EPI formula using standardized serum creatinine measurement, a procedure of creatinine testing calibrated to a traceable reference method (Isotope Dilution Mass Spectrometry or IDMS). Mean annual decline in GFR was estimated by the ratio between retrospective data indicating changes in GFR and follow-up duration (recent eGFR–eGFR at initial visit)/follow-up duration (years). Mean follow-up period was 4 years (3-7 years).

All patients underwent a screening for diabetes mellitus by measuring fasting serum glucose (FPG) and glycated hemoglobin (HbA1c). A repeated FPG ≥ 126 mg/dl (7.0 mmol/l) and/or HbA1c levels of 6.5% or greater were considered diagnostic of diabetes. Hypertension was defined as a systolic blood pressure of 140 mm Hg or more, or a diastolic blood pressure of 90 mm Hg or more.

Patients with an eGFR lower than 55mL/min/1.73m², with chronic infection and/or malignancy were excluded. Twenty healthy volunteers, age- and gender-matched (ten females and ten males) were used as controls.

Sample collection and preparation

Urine samples were collected as described [20]. After overnight fasting, the second void urine sample was collected from each patient and control and immediately centrifuged at 2000 rpm for 10 min. Urine creatinine concentration was measured by the analytical BM/Hitachi 904 as described. Urine samples from healthy volunteers were pooled in order to obtain two gender-specific control groups, composed of equal urine volumes from each subject. Urinary creatinine concentration was measured in samples from each single control-subject and in pooled controls. Small molecules and salts were removed by ultra-filtration and subsequent precipitation steps.

Samples were 50-fold-concentrated using a 3kDa cut-off ultrafiltration unit (3000 NMWL, Amicon® Ultra-15 Centrifugal Filters, Merck Millipore, Tulla green Carrigtwohill, Co. Cork, Ireland) at 3000 rpm for 60 min. The recovered urine was precipitated adding cold acetone and stored at -20°C overnight. Pellets were then separated from supernatant, air-dried and re-suspended in a buffer solution consisting of 7M Urea, 2M Thiourea, 4% Chaps, 30mM Tris-HCl pH=7, 8. Two independent 10% SDS-preparative gel (16 x 20 cm) were used for female and male groups, respectively. Protein extracts from patients and control pools were resolved on a 10% 1D-SDS-polyacrylamide gel and stained as previously described [21, 22]. Each lane was cut, digested with trypsin and analyzed by LC-MS/MS [23, 24].

LC-MS/MS analysis, proteins identification and quantization

The peptide mixtures were analyzed by LC-MS/MS using a Q-Exactive™ (ThermoScientific, Bremen, Germany) coupled to an UltiMate 3000 RSLCnano LC system (ThermoScientific), including a nano-pumps binary system and a third low-pressure micro-pump. The peptide mixtures were concentrated on a trapping pre-column (Acclaim PepMap C18, 300µm x 5 mm nanoViper; 5 µm, 100 Å, Thermo Scientific), using 0.05% formic acid and 2% acetonitrile. The peptide separation was performed using a C18 column (Acclaim Easy Spray PepMap RSLC C18, 75 µm x 15cm nanoViper; 3µm, 100 Å, Thermo Scientific). Peptides were eluted with a nonlinear gradient set as follows: 4% B for 5 minutes, from 4 to 40% B in 45 minutes and from 40 to 90 % B in 1 minute at flow rate of 300nL/min. A and B mobile phases were 0.1% formic acid and 80% acetonitrile, 0, 08% formic acid respectively. The mass spectrometer Q-Exactive™ was setup in a data dependent Full MS/ddMS2, enabling the acquisition of MS/MS spectra for the ten most intense precursor ions (top ten) and dynamic exclusion of 30 sec. Resolution was set to 70000 for MS spectra acquisition and 17500 for MS/MS spectra acquisition.

Proteomic analysis was performed using ThermoProteomeDiscoverer™ platform (version 2.1.0.81; ThermoScientific), interfaced to the Sequest HT Search Engine server (University of Washington, United States) for protein identification [25]. Proteins identified by a minimum of two peptides were accepted. Only proteins identified in at least 70% of patients (5/7) underwent further analyses. The spectral counting approach was used to compare protein expression profile in patients versus control groups [26, 27]. The relative protein abundance was evaluated by the SpC log ratio (R_{SC}) [28]. To ensure the quantitative accuracy, two methods were used. To calculate each protein Normalized Spectral Abundance Factor (NSAF), the number of spectral counts (SpCs) was divided by protein length (SAF) and normalized to the sum of SAFs in a given lane. The NSAF of each 'i' protein was then normalized against urine creatinine concentration (cNSAF_i). The NSAF of each protein from the control pools was normalized by urine creatinine concentration (cNSAF_{poolfemale} and cNSAF_{poolmale}). Finally, to each 'i' protein the R_{NSAF} was calculated as the binary logarithm of a ratio of cNSAF_i versus cNSAF_{pool}.

Data mining and statistical analysis

The dataset of differentially represented proteins was analyzed using 'STRING: functional protein association networks' software 7.0 (<http://string-db.org/>) [29, 30].

The statistical analysis were carried out by means of GraphPadPrism software. The protein fold changes, expressed as R_{NSAF} , were correlated with eGFR and annual eGFR (Δ eGFR) using Pearson Correlation test. Differences were considered statistically significant for p-values < 0.05.

Table 1. Clinical features of female BBS patients. BMI, Body Mass Index; eGFR, Estimated Glomerular Filtration Rate; PCR, urine protein to creatinine ratio

Description	X1	X2	X3	X4	X5	X6	X7
Age	43	27	19	19	18	25	22
BMI, kg/m ²	32.3	27	28.9	32	29.8	42.8	30
Retinal degeneration	+	+	+	–	+	+	+
Polydactyly	+	+	+	+	–	+	–
Learning disabilities	–	+	+	+	+	–	–
Renal structural abnormalities	+	+	+	+	–	+	+
PCR (mg/g)	132	82	87	85	73	45	43
eGFR	87.6	72.7	111.9	130	128.6	81.2	111.3
Δ eGFR/year	–4.7	–6.5	–2.8	0.8	0.2	–4.5	–6
Diabetes	–	–	–	–	–	+	–
Hypertension	–	–	–	–	–	–	–

Table 2. Clinical features of male BBS patients. BMI, Body Mass Index; eGFR, Estimated Glomerular Filtration Rate; PCR, urine protein to creatinine ratio

Description	Y1	Y2	Y3	Y4	Y5	Y6	Y7
Age	29	30	23	27	33	27	25
BMI, kg/m ²	23	23	28	31	29.1	26	43.7
Retinal degeneration	+	+	+	+	+	+	+
Polydactyly	+	+	–	–	+	+	+
Learning disabilities	+	+	+	+	+	–	–
Renal structural abnormalities	+	+	+	–	–	–	+
PCR (mg/g)	72	86	56	55	46	45	550
eGFR	60.1	79.1	126.7	92.9	121.9	119.2	55.6
Δ eGFR/year	–10.1	–3.4	–2	–1	–0.7	–1.1	–4.2
Diabetes	–	–	–	–	–	–	+
Hypertension	+	–	–	–	–	–	+

Results

Cohort

Fourteen adult BBS patients with clinical diagnosis of BBS have been selected for the study. The main features are listed in Tables 1 and 2. Patients were aged 19–43 years old; all patients with the exception of one had retinal dystrophy; BMI ranged between 23 and 43.7 kg/m². Polydactyly and learning disabilities were present in 10/14 and 9/14 patients respectively; diabetes was present in only 1 male and 1 female patient. 2 male patients (and no any female patient) were hypertensive. Renal structural abnormalities on ultrasound were present in 10/14 patients, with calyceal and parenchymal cysts, unilateral renal hypoplasia, ureteric tract malformation being the most common defects. Protein to creatinine ratio (PCR) was over 150 mg/g in one male patient. The estimated GFR ranged from 55 to 130 mL/min/1.73m². Annual GFR decline varied among subjects; interestingly, the majority of patients showed a progression of kidney disease.

Urine proteome of BBS patients

Two independent gender comparative analyses were performed. Urine proteomes of 7 female and 7 male BBS subjects were compared with the proteome of the gender-matched control pool. Urinary proteins were resolved on a 10% 1D-SDS-polyacrylamide gel as shown in Fig. 1. Gel bands were cut and proteins identified by LC-MS/MS. The analysis revealed a dataset constituted by 73 and 66 proteins in female and male patients, respectively. The details of protein identification is reported in supplementary Tables 1S and 2S. For all supplemental material see www.karger.com/doi/10.1159/000488096.

Label-free proteomic analysis was performed to compare proteome composition between patients and controls. In order to estimate the differences in urine proteome, the relative abundance of each protein was calculated by two spectral counting parameters, R_{SC} and R_{NSAF} . Female and male datasets are reported in Table 3 and Table 4, respectively. Fig. 2 shows the urine protein abundance (fold changes) based on R_{SC} and R_{NSAF} in female (Fig. 2A) and male (Fig. 2B) BBS individuals. The results were similar in both conditions, confirming the reliability of the quantitative analysis of this study. Female dataset showed 23

over-represented proteins and 42 under-represented proteins compared with the control pool. Male dataset showed 27 over-represented proteins and 36 under-represented proteins compared with the control. 42 proteins were de-regulated in both male and female BBS individuals compared with controls (Table 5). Fig. 3 shows that the majority of these proteins had the same behavior in both female and male BBS; however, some of them showed an opposite abundance in males and females, thus suggesting an inter-gender variability.

Urinary extracellular matrix organization (ECM) proteins and cell adhesion molecules (CAM) were highly deregulated in BBS patients

Protein association networks were analyzed using STRING database (<http://string-db.org/>). Proteins were grouped according to the biological and functional connections found by Gene Ontology (GO) Database (Fig. 4). The most representative biological processes were cell adhesion (13 nodes, 0.00513 FDR) and extracellular matrix organization (8 nodes, 0.00776 FDR). The network distributions of the differentially represented BBS urinary proteins revealed the central role of Fibronectin.

Fibronectin (FN), lysosomal alpha-glucosidase and CD44 antigen showed a significant correlation with the eGFR in BBS patients

We verified whether urine proteins that were over or under-represented in BBS patients showed any correlation with the eGFR. Statistical analysis revealed that urine FN, CD44 antigen and lysosomal alpha-glucosidase were significantly correlated with the eGFR, as shown in Fig. 5. Interestingly, also vitronectin, IgK chain V, Ig lambda chain V and Isoform 2 of Tyrosine-protein phosphatase non-receptor type substrate 1 (SIRP- α) were significantly correlated with the eGFR in each group of female and male patients, but not when we considered the cohort in its totality (supplementary Table 3S).

Fibronectin significantly correlated with annual Δ eGFR in BBS patients

Urine proteome of BBS patients was correlated with retrospective data indicating the rate of annual change in the eGFR (Δ eGFR). The rationale of the study was to address whether patients undergoing a faster progression of renal dysfunction may show a specific set of urine proteins. This analysis revealed that urine FN was significantly correlated with the Δ eGFR. This finding is consistent with the correlation of FN with the eGFR, further supporting the hypothesis that it may be considered as a marker of kidney disease (Fig. 6).

Fig. 1. Urinary proteins from seven female BBS patients and from healthy female control pool (A) and from seven male BBS patients and from healthy male control pool (B). Proteins were resolved on 10% 1D-SDS-polyacrylamidegel, and stained by colloidal Coomassie. Each lane (X1 to X7) represents a female patient (A), similarly Y1-Y7 lanes represent each male patient (B).

Table 3. Urine protein abundance (fold changes) based on R_{SC} and R_{NSAF} in female BBS subjects

Accession	Description	R_{SC}							R_{NSAF}						
		X1	X2	X3	X4	X5	X6	X7	X1	X2	X3	X4	X5	X6	X7
O00391	Sulphydryl oxidase 1	2.2	-1.5	-1.0	-2.8	1.0	0.2	-2.0	4.2	-0.6	0.0	-4.0	1.6	0.5	-3.4
O43451	Maltase-glucoamylase, intestinal	1.1	-1.9	-2.6	-3.1	0.2	1.7	-2.4	3.1	-1.0	-1.8	-4.4	0.8	2.1	-3.8
O75594	peptidoglycan recognition protein 1	-5.7	-4.8	2.0	0.6	0.1	-3.6	-0.2	-5.4	-4.9	3.0	0.9	0.8	-3.8	-0.1
P00734	Prothrombin	-0.1	1.1	0.0	-1.6	0.5	0.7	-0.4	1.9	2.6	1.0	-1.4	1.2	1.0	-0.2
P01620	Ig kappa chain V-III region SIE	-1.4	-1.1	0.1	2.5	-0.5	-4.5	-2.9	0.5	0.3	1.2	2.8	0.1	-4.7	-3.3
P01622	Ig kappa chain V-III region TI	-3.9	-1.0	-0.4	2.8	-1.2	-5.7	-2.6	-2.2	0.4	0.7	3.1	-0.5	-6.9	-2.9
P01623	Ig kappa chain V-III region WOL	-1.5	-1.0	0.1	2.5	-0.5	-4.5	-3.0	0.5	0.5	1.2	2.8	0.1	-4.7	-3.3
P01699	Ig lambda chain V-I region VOR	0.5	-2.8	1.8	-0.1	0.6	-1.6	-1.7	2.4	-2.9	2.9	0.0	1.3	-1.8	-3.0
P01834	Ig kappa chain C region	-7.3	-3.2	-0.6	-0.9	-3.5	-4.0	-5.3	-7.0	-1.9	0.4	-0.6	-2.9	-3.8	-6.7
P02647	Apolipoprotein A-I	-1.3	2.0	-2.3	3.5	3.2	1.6	2.4	-0.7	3.4	-2.6	3.9	4.1	1.9	2.3
P02751	Fibronectin	0.7	0.1	-2.7	-0.2	-0.8	-1.4	-3.1	2.6	1.5	-1.6	0.1	-0.1	-1.1	-3.4
P02760	Protein AMBP	1.0	1.6	0.8	2.4	-0.1	0.0	-1.7	2.9	3.0	1.8	2.5	0.6	0.3	-1.4
P02763	Alpha-1-acid glycoprotein 1	0.1	3.2	-6.9	1.7	1.2	3.9	1.6	2.0	4.6	-7.4	2.1	1.9	4.2	1.8
P02769	Serum Albumin	0.4	-0.7	-0.7	1.7	-0.7	-0.1	0.4	2.3	0.7	-0.4	-1.4	-0.1	0.3	0.6
P04004	Vitronectin	-1.8	-4.0	-1.3	-0.2	-1.0	-2.9	-2.9	0.0	-4.1	-0.3	0.0	-0.4	-3.0	-4.3
P04206	Ig kappa chain V-III region GOL	-3.9	-1.0	-0.3	2.9	-1.1	-5.7	-2.6	-2.3	0.4	0.7	3.2	-0.5	-6.9	-2.9
P04208	Ig lambda chain V-I region WAH	0.3	-3.0	1.5	2.2	0.5	-1.8	-1.9	2.2	-3.1	2.6	2.6	1.2	-2.0	-3.3
P04746	Pancreatic alpha-amylase	0.3	-0.9	-0.9	-2.9	-0.6	1.2	-0.5	-2.3	0.6	0.2	-2.8	0.0	1.6	-0.4
P05451	Lithostathine-1-alpha	-1.2	-1.8	0.6	-3.1	-0.4	-2.2	-2.3	0.6	-0.9	1.7	-4.3	0.2	-2.4	-3.7
P06702	Protein S100-A9	-0.1	0.0	-4.3	-2.0	-1.4	0.0	0.3	1.7	1.2	-4.8	-3.2	-1.0	0.2	0.0
P07858	Cathepsin B	-0.2	2.8	-3.5	1.1	-0.2	0.7	0.3	1.7	4.3	-3.0	1.4	0.5	1.0	0.3
P07911-5	Isoform 5 of Uromodulin	-2.0	-2.6	-1.0	-2.1	-0.6	-1.4	-0.7	0.0	-1.1	0.2	-1.6	0.1	-1.0	-0.5
P07998	Ribonuclease pancreatic	2.8	3.4	-1.9	0.7	-2.2	1.8	-4.6	4.7	4.8	-0.9	1.0	-1.5	2.2	-6.0
P08571	Monocyte differentiation antigen CD14	-6.5	-3.9	-1.5	0.3	0.4	-5.9	-0.7	-6.1	-3.0	-0.4	0.7	1.0	-7.2	-0.6
P09603	Macrophage colony-stimulating factor 1	-1.6	-0.4	-4.5	-0.6	-1.9	0.2	0.7	0.2	1.0	-4.0	-0.4	-1.3	0.6	0.8
P10153	Non-secretory ribonuclease	-0.2	2.1	-1.1	-0.8	-0.6	1.2	-0.5	1.7	3.4	0.0	-0.4	0.1	1.5	-0.2
P10253	lysosomal alpha-glucosidase	2.1	-1.0	-0.4	-2.6	-0.4	0.5	-1.2	-4.0	0.4	0.7	-2.5	0.3	0.8	-1.1
P12036	Neurofilament heavy polypeptide	-2.9	-1.2	0.1	-3.2	-0.5	-2.4	-2.4	-1.5	0.0	1.1	-4.4	0.2	-2.5	-3.8
P12830	Cadherin-1	1.6	1.8	-2.3	1.2	0.5	2.7	0.4	3.5	3.3	-1.3	1.6	1.2	3.0	0.6
P13646	Keratin, type I cytoskeletal 13	-1.3	-2.4	-0.1	-2.6	-0.7	-1.8	-3.1	0.7	-0.9	1.0	-2.3	0.0	-1.5	-3.1
P13987	CD59 glycoprotein	-2.7	-0.9	-7.1	-4.8	-4.2	-2.4	-2.5	-0.8	0.5	-7.7	-6.1	-3.8	-2.2	-2.8
P14384	Carboxypeptidase M	-3.0	-2.0	-3.3	-3.3	0.2	1.1	-2.5	-1.6	-1.1	-2.5	-4.5	0.9	1.5	-3.9
P14923	Junction plakoglobin	-2.5	2.3	-0.4	1.1	1.5	1.9	-0.5	-2.1	3.8	0.6	1.2	2.2	2.3	-1.8
P15289-1	arylsulfatase A	3.0	2.0	-1.1	-3.5	0.3	2.5	-2.8	4.9	3.5	0.0	-4.8	1.0	2.9	-4.2
P15924-1	Desmoplakin	-0.9	0.9	-0.4	0.4	1.4	1.3	0.6	0.8	2.3	0.7	0.5	2.1	1.7	0.6
P16070	CD44 antigen	0.3	0.9	-1.0	-0.9	-0.3	0.9	0.7	2.2	2.4	0.1	-0.6	0.3	1.3	1.0
P16278	Beta-galactosidase	2.7	0.2	-0.4	-1.8	1.0	0.9	-1.1	4.7	1.4	0.6	-3.0	1.7	1.2	-2.4
P17900	Ganglioside GM2 activator	-4.1	-0.3	-2.3	-0.5	-2.7	-2.0	-2.1	-3.8	0.9	-1.4	-0.4	-2.4	-2.2	-3.4
P19652	Alpha-1-acid glycoprotein 2	-6.0	0.0	-7.0	1.9	0.1	0.3	0.6	-5.7	1.4	-7.6	2.2	0.8	0.6	0.8
P19961	Alpha-amylase 2B	0.4	-0.7	-0.7	-2.7	-0.4	1.4	-0.3	-2.3	0.7	0.3	-2.6	0.2	1.7	-0.2
P22105-4	Isoform 5 of Tenascin-X	0.5	1.5	-1.7	-3.1	0.6	-1.1	-2.4	2.4	2.9	-0.8	-4.4	1.3	-0.9	-3.8
P24821	Tenascin	3.7	3.0	-0.9	1.4	1.5	1.7	-0.7	5.7	4.5	0.0	1.6	2.2	2.1	-2.0
P25311	Zinc-alpha-2-glycoprotein	1.9	-4.4	-0.3	-2.5	0.6	-3.3	-3.4	3.9	-4.6	0.8	-2.7	1.3	-3.5	-4.7
P29508	Serpin B3	-2.4	-1.1	-4.7	-4.0	-1.7	1.9	-3.2	-0.7	0.2	-4.2	-5.2	-1.1	2.3	-4.6
P31944	Caspase-14	1.1	1.3	-2.3	1.6	2.2	0.8	2.4	2.9	2.4	-2.6	1.6	3.0	0.9	2.3
P41222	Prostaglandin-H2 D-isomerase	1.9	1.4	1.1	0.0	0.2	0.6	-0.5	3.8	2.9	2.2	0.4	0.9	1.0	-0.3
P43652	Afamin	3.3	3.5	-3.2	3.5	0.4	-1.6	2.2	5.3	5.0	-3.6	3.9	1.0	-2.8	2.3
P48594	Serpin B4	-0.5	0.2	-3.9	-0.8	0.1	2.7	-2.4	1.3	1.6	-3.3	-0.8	0.7	3.1	-3.8
P62736	Actin, aortic smooth muscle	0.7	0.7	-3.0	-0.7	-0.1	1.2	-2.7	2.6	2.1	-2.1	-0.5	0.6	1.5	-4.1
P78324-2	Isoform 2 of Tyrosine-protein phosphatase non-receptor type substrate 1	-2.5	-3.1	-0.3	-0.5	1.3	-2.0	1.2	-1.1	-3.2	0.7	-0.4	2.0	-2.1	1.3
P81605-2	Isoform 2 of Dermcidin	1.2	2.1	1.2	2.5	2.7	3.6	2.7	3.2	3.5	2.3	2.9	3.4	4.0	2.9
P98160	Basement membrane-specific heparan sulfate proteoglycan core protein	1.5	-0.5	-1.0	-0.8	-0.6	-1.6	-2.1	-3.4	0.9	0.1	-0.4	0.1	-1.3	-1.9
P98164	Low-density lipoprotein receptor-related protein 2	-3.2	1.6	-3.0	0.2	2.2	-1.5	0.0	-1.9	3.1	-2.2	0.4	-2.9	-1.3	0.1
Q02413	Desmoglein-1	-2.5	3.0	-2.0	1.6	1.8	2.4	2.7	-2.1	4.4	-1.4	1.8	2.5	2.8	2.8
Q07507	Dermatopontin	-4.8	-2.3	1.1	-0.1	-0.6	-4.3	-1.2	-4.5	-1.4	2.2	0.2	0.0	-5.5	-1.5
Q13228-4	Isoform 4 of Selenium-binding protein 1	3.0	-1.6	-2.0	0.3	-0.7	-0.4	-0.5	5.0	-1.7	-1.4	0.2	-0.1	-0.5	-1.8
Q14624-1	Inter-alpha-trypsin inhibitor heavy chain H4	-5.5	-4.6	-3.1	0.7	-0.3	-3.4	-0.7	-5.2	-4.7	-2.1	1.0	0.4	-3.6	-0.6
Q16270-1	Insulin-like growth factor-binding protein 7	0.3	0.7	-2.7	-0.7	-1.2	-1.4	-2.6	2.3	2.2	-1.7	-0.4	-0.5	-1.1	-2.9
Q5ZPR3	CD276 antigen	-4.1	0.9	-3.6	-2.8	0.9	-2.0	0.2	-3.8	2.3	-3.0	-4.1	1.6	-2.2	0.2
Q6EMK4	vasorin	-2.5	-5.3	-5.7	-0.9	1.1	-5.7	0.2	-0.7	-5.4	-5.2	-0.6	1.8	-7.0	0.4
Q6GTX8	Leukocyte-associated immunoglobulin-like receptor 1	0.9	-0.1	-0.2	-2.5	-0.2	-2.3	-2.9	2.8	1.4	0.9	-2.3	0.4	-2.0	-3.2
Q6ISS4	Leukocyte-associated immunoglobulin-like receptor 2	0.6	-1.3	0.3	-2.6	0.0	-3.4	-3.4	2.6	0.0	1.3	-2.8	0.7	-3.5	-4.8
Q8N1N4	Keratin, type II cytoskeletal 78	-2.2	-0.4	0.3	-0.9	0.0	-3.2	-1.7	-0.8	0.7	1.4	-1.0	0.6	-4.4	-3.0
Q8TDQ0	Hepatitis A virus cellular receptor 2	-1.6	1.3	-3.3	-1.5	-0.1	0.0	-1.5	0.2	2.8	-2.4	-1.4	0.6	0.3	-1.8
Q8WVN6	Secreted and transmembrane protein 1	-0.6	-1.9	-4.2	-0.2	-1.9	-3.0	-0.8	1.3	-0.5	-3.2	0.2	-1.3	-2.8	-0.7
Q969P0	Immunoglobulin superfamily member 8	-3.3	-2.3	1.3	-0.8	-0.3	-2.1	-1.3	-1.9	-1.4	2.4	-0.6	0.4	-2.0	-1.6
Q96FE7-1	Phosphoinositide-3-kinase-interacting protein 1	0.8	0.3	-0.3	-2.8	0.1	-0.8	-1.2	-2.7	1.8	0.8	-2.7	0.8	-0.5	-1.1
Q96RW7-1	Hemicentin-1	1.7	2.4	-0.6	-0.8	0.9	0.2	-2.3	3.6	3.9	0.4	-0.7	1.5	0.6	-3.7
Q99715-1	Collagen alpha-1(XII) chain	1.3	1.6	-2.5	1.2	-0.3	-1.0	-2.3	-3.3	3.0	-1.7	1.5	0.3	-0.8	-3.7
Q9H299	SH3 domain-binding glutamic acid-rich-like protein 3	2.0	2.5	4.1	-1.1	0.2	-0.3	-0.3	4.0	4.0	5.2	-2.2	0.8	-0.4	-1.6
Q9H3G5	Probable serine carboxypeptidase CPVL	0.3	2.9	-0.7	0.0	0.6	0.8	0.8	1.9	4.4	0.0	-1.0	1.3	0.9	-0.4
Q9HCU0	endosalin	-1.8	-0.3	0.5	-3.4	0.5	-4.9	-3.4	0.1	1.2	1.6	-3.3	1.2	-5.1	-3.7
Q9ULJ3	Protein HEG homolog 1	-1.6	-1.4	-5.0	-0.3	-0.1	-1.1	-1.9	0.0	-0.5	-5.5	-0.3	0.5	-1.0	-3.3
Q9UNN8	Endothelial protein C receptor	-5.3	-5.9	-1.3	-4.0	-0.1	-4.8	-2.5	-3.9	-6.1	-0.3	-4.2	0.6	-5.0	-2.6

Table 4. Urine protein abundance (fold changes) based on R_{SC} and R_{NSAF} in male BBS subjects

Accession	Description	R_{SC}							R_{NSAF}						
		Y1	Y2	Y3	Y4	Y5	Y6	Y7	Y1	Y2	Y3	Y4	Y5	Y6	Y7
B9A064-1	Immunoglobulin lambda-like polypeptide 5	-2,7	-2,8	-1,0	-1,8	-0,9	0,7	-1,4	-4,5	-4,6	-1,4	-1,7	-1,7	0,5	-1,3
O75594	peptidoglycan recognition protein 1	1,0	-2,1	-4,2	-3,7	-1,4	-3,4	0,0	0,8	-2,6	-5,7	-3,8	-2,1	-4,2	0,2
P00734	Prothrombin	0,2	-0,7	0,3	0,6	0,4	1,2	-0,6	-0,1	-1,0	0,4	0,7	-0,3	1,0	-0,4
P01011-1	Alpha-1-antichymotrypsin	-3,4	-1,1	-3,2	-1,6	-1,9	-0,6	-2,1	-5,2	-1,6	-4,7	-1,6	-2,7	-0,8	-2,0
P01042-2	Isoform LMW of Kininogen-1	-2,3	0,9	-3,5	0,2	-5,2	0,0	-3,0	-2,8	0,7	-3,9	0,3	-6,5	-0,2	-2,8
P01620	Ig kappa chain V-III region SIE	3,3	0,2	-0,3	-1,0	5,2	-2,7	0,4	3,2	-0,1	-0,6	-0,9	4,6	-4,3	0,7
P01622	Ig kappa chain V-III region TI	3,7	0,6	0,1	-1,0	5,6	-2,3	0,3	3,6	0,3	-0,2	-0,9	5,0	-3,9	0,6
P01623	Ig kappa chain V-III region WOL	3,3	0,2	-0,3	-0,7	5,2	-2,7	0,4	3,2	-0,1	-0,6	-0,6	4,6	-4,3	0,7
P01833	Polymeric immunoglobulin receptor	-4,1	-4,2	0,2	-0,6	-1,0	0,1	-1,4	-6,0	-6,0	0,3	-0,5	-1,8	-0,1	-1,2
P01834	Ig kappa chain C region	-3,1	-1,4	-1,4	-0,2	1,1	0,8	-3,0	-3,7	-1,7	-1,4	-0,1	0,4	0,6	-2,9
P01876	Ig alpha-1 chain C region	1,2	1,9	-3,6	-1,7	-4,6	-5,9	-0,4	1,0	1,6	-4,1	-1,6	-5,7	-7,8	-0,2
P02749	Beta-2-glycoprotein 1	-4,1	-4,2	0,2	-0,4	0,1	1,3	-1,2	-6,0	-6,0	0,3	-0,3	-0,6	1,1	-1,0
P02750	Leucine-rich alpha-2-glycoprotein	-0,3	-1,2	-2,3	-3,8	-3,3	-4,6	-3,2	-0,6	-1,6	-2,7	-4,0	-4,3	-6,4	-3,2
P02751	Fibronectin	4,2	1,1	0,1	1,7	-0,3	-1,4	-0,3	4,0	0,9	0,1	1,9	-1,0	-2,0	-0,1
P02760	Protein AMBP	0,2	0,9	0,2	0,1	1,1	1,5	-0,6	-0,1	0,6	0,3	0,1	0,2	1,1	-0,3
P02769	Serum Albumin	0,6	3,2	-0,6	1,2	-2,3	1,3	-5,0	0,3	3,0	-0,6	1,4	-3,2	1,1	-6,3
P04004	Vitronectin	0,4	-1,2	-1,0	2,1	3,2	2,4	-1,1	-0,1	-2,8	-2,3	2,5	2,7	2,5	-1,1
P04206	Ig kappa chain V-III region GOL	3,7	0,6	0,8	-1,0	5,6	-2,3	0,3	3,6	0,3	0,8	-0,9	5,1	-3,9	0,6
P04208	Ig lambda chain V-I region WAH	3,0	5,3	1,3	-2,6	1,1	1,2	-0,3	3,2	5,6	1,4	-3,6	0,8	1,3	-0,1
P04433	Ig kappa chain V-III region VG	-3,4	-1,9	-0,4	-5,5	-1,6	-2,4	-2,5	-5,2	-2,6	-0,5	-7,0	-2,4	-3,2	-2,6
P04746	Pancreatic alpha-amylase	-3,1	0,4	-0,4	-1,5	-2,9	-5,0	-0,3	-3,5	0,2	-0,3	-1,4	-3,7	-5,7	-0,1
P05154	Plasma serine protease inhibitor	-1,1	-1,4	-0,8	-2,0	-3,2	-1,7	-1,0	-1,4	-1,7	-0,8	-1,9	-4,0	-2,0	-0,8
P07858	Cathepsin B	-0,4	1,1	-0,3	2,0	-0,5	1,2	-0,3	-1,7	0,9	-1,3	2,7	-1,2	1,3	-0,1
P07911-5	Isoform 5 of Uromodulin	0,3	0,4	2,4	-0,2	-0,8	0,2	0,5	0,1	0,1	2,4	-0,1	-1,6	0,0	0,7
P07998	Ribonuclease pancreatic	1,4	0,3	0,7	1,2	0,8	1,6	0,6	1,1	0,1	0,8	1,3	0,1	1,3	0,8
P08571	Monocyte differentiation antigen CD14	1,6	-1,2	-1,6	-0,1	-2,8	-3,6	-0,6	1,4	-1,5	-1,7	0,0	-3,6	-4,4	-0,4
P09564	T-cell antigen CD7	4,9	2,7	2,9	2,4	2,7	0,5	2,5	6,2	3,5	4,0	4,0	3,4	0,3	4,1
P09603	Macrophage colony-stimulating factor 1	3,5	1,1	5,7	4,9	1,8	2,8	2,5	4,6	0,9	7,3	6,6	2,4	3,9	4,1
P0CG05	Ig lambda-2 chain C regions	-3,1	-0,4	-1,4	-2,1	-0,8	1,1	-1,8	-4,9	-0,7	-1,8	-2,1	-1,6	0,9	-1,7
P0DJ07	Pepsin A-4	1,2	-1,7	-4,6	-2,2	-3,3	1,4	1,1	0,9	-3,4	4,9	-2,5	-5,5	1,3	1,5
P10153	Non-secretory ribonuclease	-0,1	-0,5	-1,9	2,2	1,5	1,3	1,0	-0,5	-0,8	-2,3	2,3	0,8	1,1	1,2
P10253	lysosomal alpha-glucosidase	0,8	-0,7	-1,0	0,4	-2,6	-1,6	0,1	0,6	-1,0	-1,0	0,5	-3,4	-1,9	0,4
P10451-5	Isoform 5 of Osteopontin	-2,1	1,1	-2,3	-1,0	-4,7	-0,3	-1,5	-2,5	0,9	-2,3	-0,9	-5,6	-0,6	-1,2
P10909-2	Isoform 2 of Clusterin	2,0	1,9	-0,9	-2,4	-3,4	-4,0	-1,2	1,8	1,7	-1,1	-2,4	-4,7	-5,8	-1,0
P12830	Cadherin-1	-1,4	-2,7	2,0	1,3	0,4	1,4	0,5	-1,8	-3,5	2,1	1,4	-0,3	1,2	0,7
P13646	Keratin, type I cytoskeletal 13	0,0	-0,8	-2,2	0,4	0,4	-3,0	1,2	-0,4	-1,5	-3,6	0,6	-0,2	-4,7	1,5
P15289-1	arylsulfatase A	0,1	-0,4	2,6	2,4	-0,1	-3,7	0,9	-0,2	-0,7	2,7	2,6	-0,8	-5,5	1,2
P15586	N-acetylglucosamine-6-sulfatase	-4,4	-2,2	-2,7	-2,9	-1,4	-5,1	-2,7	-6,2	-2,7	-3,1	-2,9	-2,2	-6,9	-2,6
P16070	CD44 antigen	0,8	2,8	1,6	2,4	-0,9	1,2	2,0	0,5	2,7	1,7	2,6	-1,7	1,0	2,3
P18135	Ig kappa chain V-III region HAH	2,9	-0,1	-2,2	-1,3	5,0	-3,0	-0,1	2,8	-0,5	-3,6	-1,2	4,3	-4,7	0,1
P22105-4	Isoform 5 of Tenascin-X	-1,3	-3,7	-3,5	0,2	-2,9	-0,5	-0,2	-1,8	-5,5	-5,0	0,3	-3,9	-0,8	0,0
P24821	Tenascin	2,8	2,7	4,5	5,2	1,8	4,9	2,8	3,6	3,5	6,0	6,9	2,4	6,3	4,5
P25311	Zinc-alpha-2-glycoprotein	-5,3	-1,0	-2,0	-1,2	-2,0	-4,4	-2,0	-7,1	-1,3	-2,1	-1,1	-2,8	-5,1	-1,8
P30530	Tyrosine-protein kinase receptor UFO	0,3	4,5	-0,3	1,2	-3,7	-2,7	1,2	-0,1	4,4	-0,6	1,4	-5,9	-4,3	1,6
P41222	Prostaglandin-H2 D-isomerase	1,6	-0,6	1,0	-0,5	1,0	1,7	-0,2	1,3	-0,8	1,0	-0,4	0,3	1,5	0,0
P55290-4	Isoform 4 of Cadherin-13	-0,1	2,4	2,3	-0,2	-4,6	-2,0	0,9	-0,5	2,2	2,5	0,0	-6,9	-2,7	1,2
P78324-2	Isoform 2 of Tyrosine-protein phosphatase non-receptor type substrate 1	1,9	1,8	-0,3	0,9	-0,5	-1,1	0,9	1,9	1,9	-1,3	1,4	-1,2	-2,3	1,5
P80748	Ig lambda chain V-III region LOI	0,9	0,8	0,1	-2,2	0,8	0,7	0,3	0,6	0,5	0,1	-2,2	0,1	0,6	0,6
P81605-2	Isoform 2 of Dermcidin	-2,5	-2,6	-0,8	-3,1	-1,0	-0,9	0,4	-4,3	-4,4	-1,2	-3,5	-1,8	-1,3	0,6
P98160	Basement membrane-specific heparan sulfate proteoglycan core protein	1,4	-0,4	-1,6	-0,4	-1,8	-0,6	-0,4	1,1	-0,6	-1,5	-0,3	-2,5	-0,8	0,1
Q02413	Desmoglein-1	0,0	-2,4	2,1	-0,1	-2,4	-3,0	1,0	-0,4	-4,1	2,2	0,1	-3,6	-4,7	1,3
Q08380	Galectin-3-binding protein	1,8	-1,2	-1,0	0,0	-0,4	-0,6	1,1	1,5	-1,6	-1,0	0,2	-1,2	-0,9	1,3
Q14624-1	Inter-alpha-trypsin inhibitor heavy chain H4	2,7	2,7	-4,5	-1,7	-2,5	-5,2	-0,3	2,4	2,4	-6,0	-1,6	-3,4	-7,0	-0,1
Q15113	Procollagen C-endopeptidase enhancer 1	1,2	-0,5	-0,3	0,6	2,8	0,5	-0,3	0,9	-1,8	-1,3	1,1	2,6	0,3	-0,1
Q16270-1	Insulin-like growth factor-binding protein 7	-1,0	-1,1	-3,2	-0,3	-1,3	-0,1	-1,7	-1,5	-1,6	-4,7	-0,2	-2,1	-0,4	-1,6
Q6EMK4	vasorin	0,5	0,2	-3,5	-1,5	-4,8	-3,2	-1,1	0,3	-0,1	-3,7	-1,4	-5,7	-3,5	-0,9
Q6GTX8	Leukocyte-associated immunoglobulin-like receptor 1	-2,3	1,3	0,4	0,1	0,7	-3,2	-0,6	2,1	1,1	0,4	0,3	0,0	-4,9	-0,4
Q725L0-1	Vitellectin membrane outer layer protein 1 homolog	1,0	2,1	0,5	-0,8	-1,7	-2,0	-1,4	0,8	1,9	0,6	-0,6	-2,5	-2,4	-1,2
Q8N1N4	Keratin, type II cytoskeletal 78	-1,2	-1,2	1,3	1,7	1,3	1,0	1,0	-2,7	-2,8	1,4	2,1	0,8	0,9	1,5
Q8WVN6	Secreted and transmembrane protein 1	4,8	0,3	-1,0	0,1	2,5	-1,8	0,8	4,9	-0,1	-2,3	0,4	2,0	-3,3	1,2
Q8WZ75-1	Roundabout homolog 4	0,2	-3,0	-2,8	-0,9	-6,9	-5,9	-0,4	0,0	-3,5	-3,0	-0,8	-9,2	-7,7	-0,2
Q96FE7-1	Phosphoinositide-3-kinase-interacting protein 1	0,9	2,2	0,7	-0,8	-2,3	0,3	-0,8	0,6	2,0	0,8	-0,7	-3,1	0,1	-0,6
Q99715-1	Collagen alpha-1(XII) chain	1,2	1,1	-1,0	3,4	0,3	2,9	1,4	0,9	0,9	-2,3	3,8	-0,2	3,0	1,9
Q9HAT2	sialate O-acetyltransferase	0,9	-0,8	-2,2	-0,6	-2,4	-3,0	-1,0	0,6	-1,5	-3,6	-0,4	-3,6	-4,7	-0,9
Q9HCU0	endosialin	1,8	1,2	0,7	0,3	-1,2	-1,2	0,0	1,5	1,0	0,7	0,4	-2,0	-1,5	0,2
Q9ULI3	Protein HEG homolog 1	-2,7	-2,8	0,2	1,6	0,5	1,0	0,8	-4,5	-4,6	0,2	1,8	-0,2	0,8	1,1
Q9UNN8	Endothelial protein C receptor	3,0	-0,8	-2,2	-2,2	-1,6	-3,0	1,0	2,8	-1,5	-3,6	-2,2	-2,6	-4,7	1,3

Fig. 2. Urine protein abundance (fold changes) based on R_{SC} and R_{NSAF} parameters in female (A) and male patients (B) compared with the control. The Fig. shows that both methods used for protein quantization gives similar results, supporting the accuracy of the quantization.

Table 5. List of urine proteins deregulated in both female and male BBS subjects

Accession	Description
P15289-1	Arylsulfatase A
P98160	Basement membrane-specific heparan sulfate proteoglycan core protein
P12830	Cadherin-1
P07858	Cathepsin B
P16070	CD44 antigen
Q99715-1	Collagen alpha-1(XII) chain
Q02413	Desmoglein-1
Q9HCU0	endosialin
Q9UNN8	Endothelial protein C receptor
P01834	Ig kappa chain C region
P04206	Ig kappa chain V-III region GOL
P01620	Ig kappa chain V-III region SIE
P01622	Ig kappa chain V-III region TI
P01623	Ig kappa chain V-III region WOL
P04208	Ig lambda chain V-I region WAH
Q16270-1	Insulin-like growth factor-binding protein 7
Q14624-1	Inter-alpha-trypsin inhibitor heavy chain H4
P02751	Fibronectin
P81605-2	Isoform 2 of Dermcidin
P78324-2	Isoform 2 of Tyrosine-protein phosphatase non-receptor type substrate 1
P22105-4	Isoform 5 of Tenascin-X
P07911-5	Isoform 5 of Uromodulin
P13646	Keratin, type I cytoskeletal 13
Q8N1N4	Keratin, type II cytoskeletal 78
Q6GT88	Leukocyte-associated immunoglobulin-like receptor 1
P10253	lysosomal alpha-glucosidase
P09603	Macrophage colony-stimulating factor 1
P08571	Monocyte differentiation antigen CD14
P10153	Non-secretory ribonuclease
P04746	Pancreatic alpha-amylase
Q75594	peptidoglycan recognition protein 1
Q96FE7-1	Phosphoinositide-3-kinase-interacting protein 1
P41222	Prostaglandin-H2 D-isomerase
P02760	Protein AMBP
Q9ULI3	Protein HEG homolog 1
P00734	Prothrombin
P07998	Ribonuclease pancreatic
Q8WVN6	Secreted and transmembrane protein 1
P02769	Serum Albumin
P24821	Tenascin
Q6EMK4	vasorin
P04004	Vitronectin
P25311	Zinc-alpha-2-glycoprotein

Fig. 3. Urine protein abundance (fold changes, based on R_{NSAF}) limited to proteins de-regulated in both female and male patients. The picture shows that most proteins are over or under-represented in both males and females, with only few proteins showing opposite behavior.

Fig. 4. Urinary BBS proteomes were clustered by using STRING database. According to “Gene Ontology” (GO), the most significant biological processes were “Cell adhesion” and “Extracellular matrix organization”. Proteins identified in BBS proteome involved in “Cell adhesion” and in “Extracellular matrix organization” biological processes are shown in red.

Fig. 5. Correlation between eGFR and urine Fibronectin, CD44 antigen and lysosomal alpha-glucosidase in BBS patients (n = 14). eGFR is expressed in ml/min/1.73m².

Fig. 6. Correlation between annual Δ eGFR and urine Fibronectin in BBS patients ($n = 14$). Δ eGFR is expressed as ml/min/1.73m² per year. Statistical significance was determined by ANOVA.

Discussion

This is the first study to our knowledge that analyzes urine proteome in a population of adult BBS patients and correlates the spectrum of urinary proteins with renal function.

There is no doubt that urine proteomics is an emerging field that has provided new insights in the understanding of the patho-physiological mechanisms of renal and extra-renal diseases [31]. Urine is a biological fluid that can be easily collected in a non-invasive manner, and it is an important source of renal and extra-renal proteins and peptides [19]; this has raised much attention on the potentiality of this tool in the discovery of disease biomarkers [32].

Given the large genetic heterogeneity of BBS, laborious genetic tests are required for a molecular screening of patients. However, to date the diagnosis is mainly based on clinical findings [5]. Proteomics screening may be potentially of help in (I) identifying disease-specific biomarkers, useful for a more accurate diagnosis, and (II) in identifying the subset of patients at high risk of developing kidney disease, with a great impact on patients care.

The present study has investigated urine proteomic profile in adult BBS patients in comparison with age and sex-matched healthy volunteers. The results have been then stratified based on the eGFR, to address whether some classes of proteins correlated with kidney dysfunction. Finally, urine proteome of BBS patients has been correlated with retrospective data indicating the annual rate of eGFR decline.

The study shows that BBS patients have a particular urine proteome, differing from that of normal subjects. Forty-two proteins were deregulated in both male and female patients compared with control; the analysis of protein association networks revealed two networks consisting of 8 and 13 nodes respectively, extracellular matrix organization (ECM) and cell adhesion.

The association between ECM proteins and CKD has been already described in literature [33]. The putative underlying mechanism is the imbalance between ECM synthesis and degradation with subsequent fibrosis, a general pathophysiological mechanism in all types of kidney disease, independently of the initial injury [34]. Recently, Hijmans et al. have demonstrated that components of ECM proteins are detectable in the urine before the histological evidence of renal fibrosis, and have indicated urinary collagen degradation markers as potential diagnostic and predictive biomarkers of renal fibrosis [35]. In our study, ECM proteins showed different urinary abundance in BBS patients compared with controls, even in the absence of GFR decline. As all BBS patients had renal abnormalities on ultrasound, it is possible that this finding may indicate these molecules as early markers of kidney defects, that proceed GFR decline. Longitudinal studies, as well as metabolomic analysis [34], will enable us to address whether this data may predict the progression of

renal failure.

CAMs are critical for either cell-cell and cell-extracellular matrix interactions [36]. We found significant differences in urinary abundance of cadherins and integrins in BBS patients. The meaning of this association remains to be elucidated. In the best studied experimental model of ciliopathy, the autosomal dominant polycystic kidney disease (ADPKD), it has been largely demonstrated the role of polycystin-1 (PC-1) in cell-matrix and cell-cell interactions [37]. Recently, Castelli et al. have shown that PC-1 overexpression in cells leads to enhanced adhesion to the substrate, while PC-1 downregulation reduced this ability via microtubule cytoskeleton regulation [38]. It is now clear that PC-1 has also extra-cilia localization, raising the hypothesis that some features of ADPKD are based on cilia-independent cellular defects. The role of BBS genes in biological functions other than PC homeostasis has been suggested by some studies. Tobin et al. demonstrated that *BBS8* knocking down in zebrafish caused defective neural crest migration [39]. Accordingly, Hernandez et al. have demonstrated that *BBS4* and *BBS6* null cells showed deficient migration and adhesion abilities, disruption of actin stress fiber formation and focal adhesions [40], indicating a possible role of BBS genes in cytoskeleton organization and related biological processes. In a recent study we showed that *BBS10* silencing in a mouse cortical collecting duct-derived cell line led to a dramatic reduction of tubulin acetylation, associated with an impaired AQP2 trafficking to the apical membrane [9]. Whether other apical channels and/or transporters are affected remains to be elucidated [41, 42]. The molecular mechanisms linking BBS genes to cytoskeleton organization and its role in the pathophysiology of BBS defects requires additional studies. We may speculate that cytoskeleton defects can cause aberration in ciliogenesis and signaling pathways, that eventually lead to kidney and other organs defects.

The analysis of urine proteome profile with respect to the eGFR demonstrated a significant increased abundance of fibronectin, CD44 antigen and lysosomal alfa glucosidase when the GFR declines. Fibronectin is a component of the extracellular matrix, whose deposition is believed to lead to glomerular and tubular basement membrane thickening and ultimately to glomerulosclerosis and interstitial fibrosis in almost all kidney diseases [43]. The correlation between its abundance and the eGFR strongly supports the hypothesis that it may reflect renal pathology.

CD44 antigen is a transmembrane protein undetectable or barely detectable in the normal kidney, that is expressed in the proximal tubule upon ischemic injury and in renal cell tumors [44]. In mice, it is expressed during T-cell mediated tubule-interstitial nephritis, and it is believed to play a role in cell repair through cell binding to the ECM [45]. Previous proteomics studies have identified the association between CD44 antigen and renal disease in several clinical conditions, including renal transplant rejection, IgA nephropathy and focal segmental glomerulosclerosis (FSGS) [46, 47]. Our findings confirm that this protein correlates with renal dysfunction also in BBS. The increased urinary abundance of the lysosomal alfa glucosidase is more difficult to interpret. The protein has a crucial role in glycogen degradation to glucose, and its dysfunction due to mutations in the *GAA* gene leads to the glycogen storage disease type II (Pompe disease). The protein is largely expressed in the proximal tubule (PT). Whether the increased urinary abundance in patients with lower GFR is a generic marker of nephron disruption remains to be elucidated. The current data do not support a possible role of general or specific PT dysfunction in BBS patients, but further studies are needed to answer this questions [48].

A series of proteins, including vitronectin, Ig kappa chain V-III Isoform 2 and Tyrosine-protein phosphatase non-receptor type substrate 1 (SIRP- α) were significantly correlated with the eGFR separately in woman and men but not when we considered the whole cohort, maybe for the inter-gender variability [49, 50]; it is not excluded that they may be part of a panel of proteins that reflect kidney dysfunction.

Finally, urine proteomes were analyzed based on mean annual eGFR decline. Interestingly, the majority of BBS patients showed a progressive decline of the eGFR, suggesting that those patients are at high risk to develop kidney failure. Whether intrinsic factors related

to the genetic disease or common risk factors, as hypertension, diabetes and obesity may play a role in GFR decline is currently unknown and is object of intensive investigations. In our cohort there is a little presence of diabetic patients, and only 2 of 14 patients were hypertensive; surely these conditions may play a role in kidney disease progression, as in general population, but the evidence of GFR decline in non hypertensive and non diabetic patients suggests that other factors may participate in the pathogenesis of GFR decline. Larger studies are needed to address whether obesity may play a more significant role.

Interestingly, our data demonstrate a significant correlation between fibronectin and Δ eGFR. This finding further confirms the importance of this protein as a marker of kidney disease.

Besides the proteins previously described, a series of other proteins have been found over or under- represented in the urine of BBS patients compared with controls, that may be of potential interest in the understanding the pathogenesis of renal and extra renal dysfunction. Some of those proteins are surely of renal origin. It is the case of Uromodulin, whose abundance is reduced in female BBS patients, confirming our previous data [6]. The protein is kidney-specific, and is the most abundant tubular protein in normal urine [51, 52]. Recently, much attention has been paid on its urinary levels given the correlation with incident CKD and kidney disease progression [53]. Other proteins may derive from the blood, considering that whole urine samples have been used in our study. Even though we focused on kidney disease, some of our findings may shed light on extra-renal dysfunctions of BBS patients. Male BBS individuals showed a reduced urine excretion of the lysosomal enzyme N-acetylglucosamine-6-sulfatase. Protein deficiency results in the accumulation of under-degraded substrate, in mucopolysaccharidosis type IIID (Sanfilippo D syndrome), a clinical condition characterized by intellectual disability and behavioral disturbances [54]. Whether this finding may have a correlation with learning disabilities, a common feature of BBS patients, is currently unknown. In addition, both male and female BBS patients showed a reduced urine excretion of the Zinc-alpha-2-glycoprotein (ZAG). This protein is implicated in multiple biological processes, including lipid mobilization, cell cycling, tumor proliferation, and transport of nephritic by-products [55]. It has been recently recognized as a negative regulator of fibrosis progression [56], and our finding may indicate a role in renal and/or extra-renal disease in BBS.

We are aware that the current study has a number of limitations. First, pooled urine was used for proteomics analysis of the controls, and this clearly limited the interpretation of data. Second, whole urine samples have been used as source of proteins in both patients and controls, as stated above, while the recent literature has shown the advantages of using exosomes in studying renal diseases, as exosomes extraction reduces the complexity of urine and ensures the renal and urinary tract origin of the found molecules. In addition, due to sample preparation, low molecular weight proteins could have been missed, limiting the information on the whole proteome profile. Moreover, even though the number of patients with low eGFR is limited, the absence of a control group of (early stages) CKD subjects does not allow a firm conclusion on the meaning of over and under- represented proteins, as this effect may be the result of impaired renal function in general. Finally, even if the disease is rare, the number of patients is quite limited, and a larger study is required to confirm the current findings and to address whether additional pathways may be identified in the subset of patients with kidney dysfunction. To this purpose, including BBS patients with more advanced renal disease will be of help in understanding whether derangement of metabolic pathways common to CKD from any cause (as oxidative stress and sulfur aminoacid metabolism [57]) or disease-specific biological processes underlie renal disease progression and its complications [58].

However, given the rarity of the disease, the correlations we found may serve as a pilot study in the discovery of urinary markers of kidney dysfunction.

Conclusion

Our data indicate the potentiality of urine proteomics in the discovery of early markers of eGFR decline in BBS. Larger prospective studies are required to confirm these findings. The possibility to assess the risk to develop chronic kidney disease will impact the management of BBS patients, enabling to start preventive strategies in time.

Disclosure Statement

All authors declared no competing interests.

Acknowledgements

This work was supported in part by a grant from the Italian Association of Bardet-Biedl Patients (ASBBI).

References

- 1 Álvarez-Satta M, Castro-Sánchez S, Valverde D: Bardet-Biedl Syndrome as a Chaperonopathy: Dissecting the Major Role of Chaperonin-Like BBS Proteins (BBS6-BBS10-BBS12). *Front Mol Biosci* 2017;4:55.
- 2 Imhoff O, Marion V, Stoetzel C, Durand M, Holder M, Sigaudy S, Sarda P, Hamel CP, Brandt C, Dollfus H, Moulin B: Bardet-Biedl syndrome: a study of the renal and cardiovascular phenotypes in a French cohort. *Clin J Am Soc Nephrol* 2011;6:22-29.
- 3 Esposito G, Testa F, Zacchia M, Crispo AA, Di Iorio V, Capolongo G, Rinaldi L, D'Antonio M, Fioretti T, Iadicicco P, Rossi S, Franzè A, Marciano E, Capasso G, Simonelli F, Salvatore F: Genetic characterization of Italian patients with Bardet-Biedl syndrome and correlation to ocular, renal and audio-vestibular phenotype: identification of eleven novel pathogenic sequence variants. *BMC Med Genet* 2017;18:10.
- 4 Forsythe E, Sparks K, Best S, Borrowes S, Hoskins B, Sabir A, Barrett T, Williams D, Mohammed S, Goldsmith D, Milford DV, Bockenhauer D, Foggensteiner L, Beales PL: Risk Factors for Severe Renal Disease in Bardet-Biedl Syndrome. *J Am Soc Nephrol* 2017;28:963-970.
- 5 Beales PL, Elcioglu N, Woolf AS, Parker D, Flinter FA: New criteria for improved diagnosis of Bardet-Biedl syndrome: results of a population survey. *J Med Genet* 1999;36:437-446.
- 6 Zacchia M, Zacchia E, Zona E, Capolongo G, Raiola I, Rinaldi L, Trepiccione F, Ingrosso D, Perna A, Di Iorio V, Simonelli F, Moe OW, Capasso G: Renal phenotype in Bardet-Biedl syndrome: a combined defect of urinary concentration and dilution is associated with defective urinary AQP2 and UMOD excretion. *Am J Physiol Renal Physiol* 2016;311:F686-F694.
- 7 Harnett JD, Green JS, Cramer BC, Johnson G, Chafe L, McManamon P, Farid NR, Pryse-Phillips W, Parfrey PS: The spectrum of renal disease in Laurence-Moon-Biedl syndrome. *N Engl J Med* 1988;319:615-618.
- 8 Zona E, Zacchia M, Di Iorio V, Capolongo G, Rinaldi L, Capasso G: Patho-physiology of renal dysfunction in Bardet-Biedl Syndrome. *G Ital Nefrol* 2017;34:62-72.
- 9 Zacchia M, Esposito G, Carmosino M, Zacchia E, Crispo AA, Fioretti T, Trepiccione F, Di Iorio V, Simonelli F, Salvatore F, Capasso G, Svelto M, Procino G: Knockdown of the BBS10 Gene Product Affects Apical Targeting of AQP2 in Renal Cells: A Possible Explanation for the Polyuria Associated with Bardet-Biedl Syndrome. *Genet Syndr Gene Ther* 2014;5:3.
- 10 Lang F, Guelinckx I, Lemetais G, Melander O: Two Liters a Day Keep the Doctor Away? Considerations on the Pathophysiology of Suboptimal Fluid Intake in the Common Population. *Kidney Blood Press Res* 2017;42:483-494.
- 11 Zacchia M, Capasso G: Dehydration: A new modulator of klotho expression. *Am J Physiol Renal Physiol* 2011;301:F743-F744.

- 12 Zacchia M, Capolongo G, Rinaldi L, Capasso G: Renal handling of uric acid. *G Ital Nefrol* 2015;32:S62.
- 13 Zacchia M, Capolongo G, Trepiccione F, Marion V: Impact of local and systemic factors on kidney dysfunction in Bardet-Biedl Syndrome. *Kidney Blood Press Res* 2017;42:784-793.
- 14 Ansley SJ, Badano JL, Blacque OE Hill J, Hoskins BE, Leitch CC, Kim JC, Ross AJ, Eichers ER, Teslovich TM, Mah AK, Johnsen RC, Cavender JC, Lewis RA, Leroux MR, Beales PL, Katsanis N: Basal body dysfunction is a likely cause of pleiotropic Bardet-Biedl syndrome. *Nature* 2003;425:628-633.
- 15 Guo DF, Beyer AM, Yang B, Nishimura DY, Sheffield VC, Rahmouni K: Inactivation of Bardet-Biedl syndrome genes causes kidney defects. *Am J Physiol Renal Physiol* 2011;300:F574-F580.
- 16 Cognard N, Scerbo Mj, Obringer C Yu X, Costa F, Haser E, Le D, Stoetzel C, Roux MJ, Moulin B, Dollfus H, Marion V: Comparing the Bbs10 complete knockout phenotype with a specific renal epithelial knock-outone highlights the link between renal defects and systemic inactivation in mice. *Cilia* 2015;4:10.
- 17 Marion V, Schlicht D, Mockel A, Caillard S, Imhoff O, Stoetzel C, van Dijk P, Brandt C, Moulin B, Dollfus H: Bardet-Biedl syndrome highlights the major role of the primary cilium in efficient water reabsorption. *Kidney Int* 2011;79:1013-1025.
- 18 Zacchia M, Di Iorio V, Trepiccione F, Caterino M, Capasso G: The Kidney in Bardet-Biedl Syndrome: Possible Pathogenesis of Urine Concentrating Defect. *Kidney Dis (Basel)* 2017;3:57-65.
- 19 Van JA, Scholey JW, Konvalinka A: Insights into Diabetic Kidney Disease Using Urinary Proteomics and Bioinformatics. *J Am Soc Nephrol* 2017;28:1050-1061.
- 20 Beretov J, Wasinger VC, Schwartz P, Graham PH, Li Y: A standardized and reproducible urine preparation protocol for cancer biomarkers discovery. *Biomark Cancer* 2014;6:21-27.
- 21 Caterino M, Pastore A, Strozzi MG, Di Giovamberardino G, Imperlini E, Scolamiero E, Ingenito L, Boenzi S, Ceravolo F, Martinelli D, Dionisi-Vici C, Ruoppolo M: The proteome of cblC defect: *in vivo* elucidation of altered cellular pathways in humans. *J Inherit Metab Dis* 2015;38:969-979.
- 22 Caterino M, Chandler RJ, Sloan JL, Dorko K, Cusmano-Ozog K, Ingenito L, Strom SC, Imperlini E, Scolamiero E, Venditti CP, Ruoppolo M: The proteome of methylmalonic acidemia (MMA): the elucidation of altered pathways in patient livers. *Mol Biosyst* 2016;12:566-574.
- 23 Spaziani S, Imperlini E, Mancini A, Caterino M, Buono P, Orrù S: Insulin-like growth factor 1 receptor signaling induced by supraphysiological doses of IGF-1 in human peripheral blood lymphocytes. *Proteomics* 2014;14:1623-9.
- 24 Di Pasquale P, Caterino M, Di Somma A, Squillace M, Rossi E, Landini P, Iebba V, Schippa S, Papa R, Selan L, Artini M, Palamara AT, Duilio A: Exposure of *E. coli* to DNA-Methylating Agents Impairs Biofilm Formation and Invasion of Eukaryotic Cells via Down Regulation of the N-Acetylneuraminase Lyase NanA. *Front Microbiol* 2016;7:147.
- 25 Alberio T, Pieroni L, Ronci M, Banfi C, Bongarzone I, Bottoni P, Brioschi M, Caterino M, Chinello C, Cormio A, Cozzolino F, Cunsolo V, Fontana S, Garavaglia B, Giusti L, Greco V, Lucacchini A, Maffioli E, Magni F, Monteleone F, et al.: Toward the Standardization of Mitochondrial Proteomics: The Italian Mitochondrial Human Proteome Project Initiative. *J Proteome Res* 2017;16:4319-4329.
- 26 Caterino M, Aspesi A, Pavesi E, Imperlini E, Pagnozzi D, Ingenito L, Santoro C, Dianzani I, Ruoppolo M: Analysis of the interactome of ribosomal protein 19 mutants. *Proteomics* 2014;14:2286-2296.
- 27 Nigro E, Imperlini E, Scudiero O, Monaco ML, Polito R, Mazzarella G, Orrù S, Bianco A, Daniele A: Differentially expressed and activated proteins associated with non small cell lung cancer tissues. *Respir Res* 2015;16:74.
- 28 Zybaïlov B, Mosley AL, Sardi ME, Coleman MK, Florens L, Washburn MP: Statistical analysis of membrane proteome expression changes in *Saccharomyces cerevisiae*. *J Proteome Res* 2006;5:2339-2347.
- 29 Capobianco V, Caterino M, Iaffaldano L, Nardelli C, Sirico A, Del Vecchio L, Martinelli P, Pastore L, Pucci P, Sacchetti L: Proteome analysis of human amniotic mesenchymal stem cells (hA-MSCs) reveals impaired antioxidant ability, cytoskeleton and metabolic functionality in maternal obesity. *Sci Rep* 2016;6:25270.
- 30 Imperlini E, Santorelli L, Orrù S, Scolamiero E, Ruoppolo M, Caterino M: Mass Spectrometry-Based Metabolomic and Proteomic Strategies in Organic Acidemias. *Biomed Res Int* 2016;2016:9210408.
- 31 Zacchia M, Vilasi A, Capasso A, Morelli F, De Vita F, Capasso G: Genomic and proteomic approaches to renal cell carcinoma. *J Nephrol* 2011;24:155-164.
- 32 Costanzo M, Zacchia M, Bruno G, Crisci D, Caterino M, Ruoppolo M: Integration of Proteomics and Metabolomics in Exploring Genetic and Rare Metabolic Diseases. *Kidney Dis (Basel)* 2017;3:66-77.

- 33 Mullen W, Deles C, Mischak H, EuroKUP COST action: Urinary proteomics in the assessment of chronic kidney disease. *Curr Opin Nephrol Hypertens* 2011;20:654-661.
- 34 Scolamiero E, Cozzolino C, Albano L, Ansalone A, Caterino M, Corbo G, di Girolamo MG, Di Stefano C, Durante A, Franzese G, Franzese I, Gallo G, Giliberti P, Ingenito L, Ippolito G, Malamisura B, Mazzeo P, Norma A, Ombrone D, Parenti G, et al: Targeted metabolomics in the expanded newborn screening for inborn errors of metabolism. *Mol Biosyst* 2015;11:1525-1535.
- 35 Hijmans RS, Rasmussen DG, Yazdani S, Navis G, van Goor H, Karsdal MA, Genovese F, van den Born J: Urinary collagen degradation products as early markers of progressive renal fibrosis. *J Transl Med* 2017;15:63.
- 36 Bays JL, DeMali KA: Vinculin in cell-cell and cell-matrix adhesions. *Cell Mol Life Sci* 2017;74:2999-3009.
- 37 Wilson PD, Geng L, Li X, Burrow CR: The PKD1 gene product, "polycystin-1," is a tyrosine-phosphorylated protein that colocalizes with alpha2beta1-integrin in focal clusters in adherent renal epithelia. *Lab Invest* 1999;79:1311-1323.
- 38 Castelli M, De Pascalis C, Distefano G, Ducano N, Oldani A, Lanzetti L, Boletta A: Regulation of the microtubular cytoskeleton by Polycystin-1 favors focal adhesions turnover to modulate cell adhesion and migration. *BMC Cell Biol* 2015;16:15.
- 39 Tobin JL, Di Franco M, Eichers E, May-Simera H, Garcia M, Yan J, Quinlan R, Justice MJ, Hennekam RC, Briscoe J, Tada M, Mayor R, Burns AJ, Lupski JR, Hammond P, Beales PL: Inhibition of neural crest migration underlies craniofacial dysmorphology and Hirschsprung's disease in Bardet-Biedl syndrome. *Proc Natl Acad Sci U S A* 2008;105:6714-6719.
- 40 Hernandez-Hernandez V, Pravincumar P, Diaz-Font A, May-Simera H, Jenkins D, Knight M, Beales PL: Bardet-Biedl syndrome proteins control the cilia length through regulation of actin polymerization. *Hum Mol Genet* 2013;22:3858-3868.
- 41 Capasso G, Rizzo M, Garavaglia ML, Trepiccione F, Zacchia M, Mugione A, Ferrari P, Paulmichl M, Lang F, Loffing J, Carrel M, Damiano S, Wagner CA, Bianchi G, Meyer G: Upregulation of apical sodium-chloride cotransporter and basolateral chloride channels is responsible for the maintenance of salt-sensitive hypertension. *Am J Physiol Renal Physiol* 2008;295:F556-F567.
- 42 Petrazzuolo O, Trepiccione F, Zacchia M, Capasso G: Hypertension and renal calcium transport. *J Nephrol* 2010;23:S112-S117.
- 43 Hu C, Sun L, Xiao L, Han Y, Fu X, Xiong X, Xu X, Liu Y, Yang S, Liu F, Kanwar YS: Insights into the Mechanisms Involved in the Expression and Regulation of Extracellular Matrix Proteins in Diabetic Nephropathy. *Curr Med Chem* 2015;22:2858-2870.
- 44 Lewington AJ, Padanilam BJ, Martin DR, Hammerman MR: Expression of CD44 in kidney after acute ischemic injury in rats. *Am J Physiol Regul Integr Comp Physiol* 2000;278:R247-R254.
- 45 Naor D, Sionov RV, Ish-Shalom D: CD44: structure, function, and association with the malignant process. *Adv Cancer Res* 1999;71:241-319.
- 46 Sigdel TK, Kaushal A, Gritsenko M, Norbeck AD, Qian WJ, Xiao W, Camp DG 2nd, Smith RD, Sarwal MM: Shotgun proteomics identifies proteins specific for acute renal transplant rejection. *Proteomics Clin Appl* 2010;4:32-47.
- 47 Prikryl P, Vojtova L, Maixnerova D, Vokurka M, Neprasova M, Zima T, Tesar V: Proteomics approach for identification of IgA nephropathy-related biomarkers in urine. *Physiol Res* 2017;66:621-632.
- 48 Trepiccione F, Zacchia M, Capasso G: Physiopathology of Potassium Deficiency; in Alpern RJ, Caplan MJ, Moe OW (eds): Seldin and Geibisch's The Kidney Physiology and Pathophysiology (Fifth Edition). Elsevier, 2013 pp 1713-1738.
- 49 Ruoppolo M, Campesi I, Scolamiero E, Pecce R, Caterino M, Cherchi S, Mercuro G, Tonolo G, Franconi F: Serum metabolomic profiles suggest influence of sex and oral contraceptive use. *Am J Transl Res* 2014;6:614-624.
- 50 Ruoppolo M, Scolamiero E, Caterino M, Mirisola V, Franconi F, Campesi I: Female and male human babies have distinct blood 1 metabolomic patterns. *Mol Biosyst* 2015;11:2483-2492.
- 51 Zacchia M, Capasso G: The importance of uromodulin as regulator of salt reabsorption along the thick ascending limb. *Nephrol Dial Transplant* 2015;30:158-160.
- 52 Zacchia M, Capasso G: Parvalbumin: a key protein in early distal tubule NaCl reabsorption. *Nephrol Dial Transplant* 2008;23:1109-1111.

- 53 Devuyst O, Bochud M: Uromodulin, kidney function, cardiovascular disease, and mortality. *Kidney Int* 2015;88:944-946.
- 54 Beesley CE, Burke D, Jackson M, Vellodi A, Winchester BG, Young EP: Sanfilippo syndrome type D: identification of the first mutation in the N-acetylglucosamine-6-sulphatase gene. *J Med Genet* 2003;40:192-194.
- 55 Hassan MI, Waheed A, Yadav S, Singh TP, Ahmad F: Zinc alpha 2-glycoprotein: a multidisciplinary protein. *Mol Cancer Res* 2008;6:892-906.
- 56 Sörensen-Zender I, Bhayana S, Susnik N, Rolli V, Batkai S, Baisantry A, Bahram S, Sen P, Teng B, Lindner R, Schiffer M, Thum T, Melk A, Haller H, Schmitt R: Zinc- α 2-Glycoprotein Exerts Antifibrotic Effects in Kidney and Heart. *J Am Soc Nephrol* 2015;26:2659-2668.
- 57 Perna AF, Zacchia M, Trepiccione F, Ingrosso D: The Sulfur Metabolite Lanthionine: Evidence for a Role as a Novel Uremic Toxin. *Toxins (Basel)* 2017, DOI: 10.3390/toxins9010026.
- 58 Capasso R, Sambri I, Cimmino A, Salemme S, Lombardi C, Acanfora F, Satta E, Puppione DL, Perna AF, Ingrosso D: Homocysteinylation promotes increased monocyte-endothelial cell adhesion and up-regulation of MCP1, Hsp60 and ADAM17. *PLoS One* 2012;7:e31388.